Derek is a member of the corporate department at Ropes & Gray. Based in the Silicon Valley office, Derek leverages his research, academic, and consulting background to bring value to life sciences and technology clients on a variety of corporate transactions, with a particular focus on IP transactions and R&D collaborations. Derek works with clients across the company life cycle, from early-stage clients to mid-sized biotech firms and established pharmaceutical companies.
During law school, Derek was the co-editor-in-chief of the Yale Journal of Health Policy, Law, and Ethics, and was a student board member of the Solomon Center for Health Law and Policy. Derek also interned with the California Department of Justice’s Healthcare Rights and Access Section.
Prior to law school, Derek served as a life sciences consultant in Boston, where he collaborated with companies like Bayer and Pfizer to develop their business and marketing strategies. In college, Derek researched the role of TLR-7 in mediating autoimmune disease using a murine model of systematic lupus erythematosus (SLE).
Experience
- Represented SK Biopharmaceuticals, a Korea-based global biotech, in its $571.5 million exclusive license agreement with Full-Life Technologies for the development of a radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers.
- Represented Nona Biosciences in its $604 million license agreement with AstraZeneca for the development of targeted oncology therapies using Nona’s preclinical monoclonal antibodies.
- Represented Johnson & Johnson in connection with a licensing and option agreement.
- Represented Advent International in its strategic investment in Prometheus Group, a Genstar Capital portfolio company and provider of data analytics software across the pharmaceutical, chemical, and oil & gas industries.